Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

Metabolic events evaluation

Data collection methods

Secondary data collection
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

FLUTICASONE PROPIONATE
CICLESONIDE
BECLOMETASONE DIPROPIONATE

Medical condition to be studied

Chronic obstructive pulmonary disease
Pneumonia
Diabetes mellitus
Population studied

Short description of the study population

Obstructive lung disease patients initiating and stepping-up their Inhaled corticosteroids (ICS) therapy.

Age groups

Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Chronic obstructive pulmonary disease (COPD) patients

Estimated number of subjects

10000
Study design details

Main study objective

Compare for large particle vs small particle ICS:Diagnosis of pneumonia First diagnosis of type 2 diabetes and/or prescription for anti-diabetic medication Progression of ongoing type 2 diabetes treatment to insulinChange in anti-diabetic medication (e.g. type or dose prescribed) Change in HbA1c valueChange in BMI

Outcomes

Co-primary outcomes:(i) First diagnosis of diabetes and/or prescription for anti-diabetic medication (ii) Progression of ongoing diabetes treatment to insulin(iii) Change in HbA1c value(iv) Change in anti-diabetic medication (e.g. type or dose prescribed) (v) Change in BMI (vi) Diagnosis of pneumonia (vii) Exacerbation of obstructive lung disease

Data analysis plan

Treatment arms will be compared using (conditional) logistic regression, Poisson regression and Cox regression.